Recombinant EPO production - Points the nephrologist should know

Nephrology Dialysis Transplantation

Volumn 22, Issue 10, 2007, Pages 2749-2753

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Biopharmaceuticals; Erythropoiesis stimulating agents; Erythropoietin; Recombinant; Renal anemia

Indexed keywords

EPOMAX; HEMATIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RO 50 3821; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CHO CELL; CHRONIC KIDNEY DISEASE; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NONHUMAN; NOTE; PLASMA HALF LIFE; PRIORITY JOURNAL; RETICULOCYTOSIS;

ANEMIA; ANIMALS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; DRUG DESIGN; ERYTHROPOIETIN, RECOMBINANT; GLYCOSYLATION; HUMANS; KIDNEY DISEASES; NEPHROLOGY;

EID: 36049007201     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm392     Document Type: Note

References (37)

1. World Health Organization. International nonproprietary names (INN) for biological and biotechnological substances. INN Working Document 05.179, 1-29. 2006
2. Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 1987; 262: 17156-17163
3. Rahbek-Nielsen H, Roepstorff P, Reischl H et al. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrometry 1997; 32: 948-958
4. Storring PL, Tiplady RJ, Gaines DR et al. Epoetin-α and -β differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89
5. Rush RS, Derby PL, Smith DM et al. Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 1995; 67: 1442-1452
6. Weikert S, Papac D, Briggs J et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999; 17: 1116-1121
7. Goto M, Akai K, Murakami A et al. Production of recombinant human erythropoietin in mammalian cells: host-cell dependency of the biological activity of the cloned glycoprotein. Bio/Technology 1988; 6: 67-71
8. Hayakawa T, Wada M, Mizuno K et al. In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals 1992; 20: 253-257
9. Inoue N, Takeuchi M, Ohashi H et al. The production of recombinant human erythropoietin. Biotechnol Annu Rev 1995; 1: 297-313
10. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin-α and epoetin-β. Clin Pharmacol Ther 1991; 50: 702-712
11. Stockenhuber F, Loibl U, Gottsauner-Wolf M et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399-402
12. Deechongkit S, Aoki KH, Park SS et al. Biophysical comparability of the same protein from different manufacturers: a case study using epoetin-α from Epogen and Eprex. J Pharm Sci 2006; 95: 1931-1943
13. Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353
14. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408
15. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. CHMP/BMWP/42832/2005, 2006
16. Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006; 21 [Suppl 5]: v17-v20
17. Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as activated substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/ 94526/2005 Corr 2006
18. Derouazi M, Martinet D, Besuchet SN et al. Genetic characterization of CHO production host DG44 and derivative recombinant cell lines. Biochem Biophys Res Commun 2006; 340: 1069-1077
19. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25: 954-962
20. Nimtz M, Wray V, Rudiger A et al. Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 1995; 365: 203-208
21. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626-3634
22. The Court Service - Court of Appeal - Civil - Judgment. Neutral Citation Number: [2002] EWCA Civ. 1096. 2002. www.hmcourts-service.gov.uk/judgmentsfiles/ j1329/Kirin_v_Hoechst.htm
23. Cointe D, Beliard R, Jorieux S et al. Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology 2000; 10: 511-519
24. Shahrokh Z, Flatman S, Davies M, Baycroft A, Heartlein M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Haematologica 2006; 91 [S1]: 208 (Abstract)
25. Noguchi A, Mukuria CJ, Suzuki E et al. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem (Tokyo) 1995; 117: 59-62
26. Tangvoranuntakul P, Gagneux P, Diaz S et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003; 100: 12045-12050
27. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005; 175: 228-236
28. Kwan JT, Pratt RD. Epoetin-δ, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007; 23: 307-311
29. Spinowitz BS, Pratt RD. Epoetin-δ is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006; 22: 2507-2513
30. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84: 3-10
31. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-421
32. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69: 265-274
33. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375-381
34. Wish JB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int 2006; 70: S21-S25
35. MacDougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436-440
36. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830-1834
37. Kochendoerfer GG. Site-specific polymer modification of therapeutic proteins. Curr Opin Chem Biol 2005; 9: 555-560